The following chart is a simplified representation of the recommended therapeutic options for aHUS from Zuber et al.’s 2012 paper, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
To access a slide containing the full, detailed chart, please click here.
To download the PDF version of aHUS Canada’s simplified chart (seen below), please click here.
 Chart adapted from Zuber, J. et al. Nat. Rev. Nephrol. 8, 643–657 (2012); published online 2 October 2012; doi:10.1038/nrneph.2012.214
 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V on behalf of the French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012:8:643-657.
 Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279.
 Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010:36(6):673-681.
 Noris M and Remuzzi G. Review Article: Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2009;361:1676-87.
 Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non–Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99.
 Legendre C.M., Licht, C., Muus P. et al. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2013;368:2169-81.